-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

Benzinga·08/14/2026 13:07:23
语音播报
Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.